Available to mentor
Dr. Peter Higgins received his bachelor's degree and medical degrees from Duke University, and completed a Ph.D. in molecular cancer biology at Duke. He completed a fellowship in gastroenterology at the University of Michigan in 2004, completed an M.Sc. in Clinical Research Design and Statistical Analysis at the University of Michigan School of Public Health, and joined the University of Michigan faculty the same year. Dr. Higgins currently serves as the IBD editor for the American Journal of Gastroenterology. His research focuses on inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. He is interested in the molecular mechanisms of intestinal fibrosis, which leads to intestinal blockages and surgery. Dr. Higgins studies the use of ultrasound to measure intestinal scarring, the use of biomarkers to detect early scarring, and measurement of markers of early inflammation. His clinical research includes studies on patient-reported outcomes in IBD, medication holidays after long-term remission in IBD, and biomarker-guided therapy in IBD. Dr. Higgins' research interests are complemented by his clinical interest in improving the quality of care of patients with IBD. He is a member of the AGA IBD Quality Measures Committee, and has participated in the development of national guidelines for high quality IBD care. Dr. Higgins has received many honors and awards, including the AGA IBD Clinical Research Excellence Award.
Higgins IBD Program
Detection and measurement of inflammation in inflammatory bowel disease (IBD). Mechanisms of intestinal fibrosis, and measurement of fibrosis with ultrasound and biomarkers. Medication holidays after long-term IBD remission. Patient-reported outcomes in IBD.
-
Sheehan JL, Jordan AA, Newman KL, Johnson LA, Eloubeidi D, Cohen-Mekelburg S, Berinstein JA, Tipirneni R, Higgins PDR. Inflamm Bowel Dis, 2024 Oct 3; 30 (10): 1696 - 1706.Journal ArticleAre Depression and Anxiety Underdiagnosed in Socially Vulnerable Patients With Inflammatory Bowel Disease?
DOI:10.1093/ibd/izad246 PMID: 37878586 -
Constant BD, Long MD, Scott FI, Higgins PDR. Am J Gastroenterol, 2024 Oct 1; 119 (10): 2070 - 2078.Journal ArticleInsurer-Mandated Medication Utilization Barriers are Associated With Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An Inflammatory Bowel Disease Partners Survey.
DOI:10.14309/ajg.0000000000002851 PMID: 38819004 -
Noureldin M, Van T, Cohen-Mekelburg S, Scott FI, Higgins PDR, Stidham RW, Hou J, Waljee AK, Berinstein JA. Am J Gastroenterol, 2024 Oct 1; 119 (10): 2130 - 2133.Journal ArticleLegalization of Cannabis Does Not Reduce Opioid Prescribing in Patients With Inflammatory Bowel Disease: A Difference-in-Difference Analysis.
DOI:10.14309/ajg.0000000000002834 PMID: 38767951 -
Kathuria P, Higgins PDR, Berinstein JA. Am J Gastroenterol, 2024 Oct 1; 119 (10): 2139 - 2140.Journal ArticleTiming Is Everything: The Lifesaving Potential of Early Medical Therapy in Acute Severe Ulcerative Colitis.
DOI:10.14309/ajg.0000000000002867 PMID: 38864521 -
Romain D, Larson C, Kathuria P, Aintabi D, Tedesco N, Saunyama Q, DeJonckheere M, Bishu S, Cohen-Mekelburg S, Higgins PDR, Berinstein JA. Dig Dis Sci, 2024 Oct; 69 (10): 3690 - 3700.Journal ArticleUnderstanding the Perspectives and Experiences of Patients with Acute Severe Ulcerative Colitis in the Hospital: A Qualitative Analysis.
DOI:10.1007/s10620-024-08633-0 PMID: 39294423 -
Xue M, Leibovitzh H, Jingcheng S, Neustaeter A, Dong M, Xu W, Espin-Garcia O, Griffiths AM, Steinhart AH, Turner D, Huynh HQ, Dieleman LA, Panaccione R, Aumais G, Bressler B, Bitton A, Murthy S, Marshall JK, Hyams JS, Otley A, Bernstein CN, Moayyedi P, El-Matary W, Fich A, Denson LA, Ropeleski MJ, Abreu MT, Deslandres C, Cino M, Avni-Biron I, Lee S-H, Turpin W, CCC GEM Project Research Consortium , Croitoru K. Clin Gastroenterol Hepatol, 2024 Sep; 22 (9): 1889 - 1897.e12.Journal ArticleEnvironmental Factors Associated With Risk of Crohn's Disease Development in the Crohn's and Colitis Canada - Genetic, Environmental, Microbial Project.
DOI:10.1016/j.cgh.2024.03.049 PMID: 38759825 -
Kayal M, Spencer EA, Smyth M, Raffals L, Qazi T, Deepak P, Beniwal-Patel P, Chang S, Higgins P, Cross RK, Anderson C, Long M, Herfarth HH, Dubinsky MC, Barnes EL. Inflamm Bowel Dis, 2024 Jul 22;Journal ArticleRisankizumab Is Effective for The Management of Crohn's Disease of the Pouch.
DOI:10.1093/ibd/izae164 PMID: 39038228 -
Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, Click B, Steiner CA, Dulaney D, Levine J, Hassan SA, Perry C, Flomenhoft D, Ungaro RC, Berinstein EM, Sheehan J, Cohen-Mekelburg S, Regal RE, Stidham RW, Bishu S, Colombel J-F, Higgins PDR. Am J Gastroenterol, 2024 Mar 27;Journal ArticleEffectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience.
DOI:10.14309/ajg.0000000000002674 PMID: 38275248